Literature DB >> 19959805

Comparative effectiveness: a table of expected benefits and harms.

Michael W Kattan1.   

Abstract

Mesh：

Year:  2009        PMID： 19959805     DOI： 10.1177/0272989X09351585

Source DB:  PubMed          Journal:  Med Decis Making        ISSN： 0272-989X            Impact factor:   2.583


× No keyword cloud information.
  4 in total

1.  Modeling potential time to event data with competing risks.

Authors:  Liang Li; Bo Hu; Michael W Kattan
Journal:  Lifetime Data Anal       Date:  2013-09-24       Impact factor: 1.588

Review 2.  Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?

Authors:  Hetty Helsmoortel; Celine Everaert; Nicolaas Lumen; Piet Ost; Jo Vandesompele
Journal:  Noncoding RNA Res       Date:  2018-05-23

3.  Head to head randomized trial of two decision aids for prostate cancer.

Authors:  Angela Fagerlin; Margaret Holmes-Rovner; Timothy P Hofer; David Rovner; Stewart C Alexander; Sara J Knight; Bruce S Ling; James A Tulsky; John T Wei; Khaled Hafez; Valerie C Kahn; Daniel Connochie; Jeffery Gingrich; Peter A Ubel
Journal:  BMC Med Inform Decis Mak       Date:  2021-05-12       Impact factor: 2.796

4.  The risk matrix approach: a helpful tool weighing probability and impact when deciding on preventive and diagnostic interventions.

Authors:  Stéphanie M P Lemmens; Veronica A Lopes van Balen; Yvonne C M Röselaers; Hubertina C J Scheepers; Marc E A Spaanderman
Journal:  BMC Health Serv Res       Date:  2022-02-17       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.